Dr Eddie Blair United Kingdom

IMS offers magnetic antibodies and adaptor proteins to the life science community (research and bioprocessing) while further developing the technology platform for licensing and partnering opportunities in medicine (diagnostics and therapeutics).

Organisation Type
Integrated Magnetic Systems Ltd
Chief Executive Officer 

Dr John Burt United Kingdom

PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Organisation Type
PolyTherics Ltd
Chief Executive Officer 

Mr Andy Bush United Kingdom

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.

Organisation Type
Prosonix Ltd
Chief Operating Officer 

Mr Jeremy Curnock Cook United Kingdom

IBML, through its associate companies, OctaPhillip Bioscience Managers Ltd and Union MedTech PLC, specialises in investment in life science and medical technology companies.

Organisation Type
International Bioscience Managers
Managing Director 

Dr Jennifer Filbey United Kingdom

PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Organisation Type
PolyTherics Ltd
US consultant 

Mr David Hipkiss United Kingdom

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.

Organisation Type
Prosonix Ltd
Chief Executive Officer 

Dr Sarah Howell United Kingdom

Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines, monoclonal antibodies, peptides, blood factors and fusion proteins

Website:
www.arecor.com
Organisation Type
Arecor Ltd
Chief Operations Officer 

Dr Eddy Littler United Kingdom

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates

Organisation Type
Domainex
Chief Executive Officer 

Dr Tim Mitchell United Kingdom

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease.

Website:
www.sareum.co.uk
Organisation Type
Sareum Ltd
Chief Executive Officer 

Dr Ben Nichols United Kingdom

Haemostatix has developed a new class of peptide-based haemostat for the treatment of bleeding. The technology is based on a peptide that binds to the blood protein fibrinogen, inducing the rapid and targeted formation of clots.

Organisation Type
Haemostatix
Chief Executive Officer